NovaBay Pharmaceuticals, Inc. (NBY)
Market Cap | 2.89M |
Revenue (ttm) | 12.14M |
Net Income (ttm) | -8.95M |
Shares Out | 1.88M |
EPS (ttm) | -5.60 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 7,843 |
Open | 1.45 |
Previous Close | 1.49 |
Day's Range | 1.45 - 1.54 |
52-Week Range | 1.24 - 12.60 |
Beta | 2.77 |
Analysts | Buy |
Price Target | 15.30 (+893.51%) |
Earnings Date | Mar 30, 2023 |
About NBY
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne unde... [Read more]
Financial Performance
In 2021, NBY's revenue was $8.42 million, a decrease of -15.23% compared to the previous year's $9.93 million. Losses were -$6.56 million, -40.58% less than in 2020.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NBY stock is "Buy." The 12-month stock price forecast is $15.3, which is an increase of 893.51% from the latest price.
News

NovaBay Pharmaceuticals to Hold 2022 Fourth Quarter and Full Year Conference Call on March 30, 2023
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2022 after marke...

Eyeganics Organic Tears, the Only USDA-Certified Organic Lubricant Eye Drop, Now Available through NovaBay Pharmaceuticals' Avenova.com and Physician-Dispensed Channel
EMERYVILLE, Calif. & KIRKWOOD, Mo.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces a partnership with Eyeganics to sell OTC Organic Tears (0.2% organic glycerin) on Ave...

NovaBay Pharmaceuticals Launches Avenova® Eye Health Support, a New Antioxidant-Rich Oral Supplement to Comfort Dry Eyes and Promote Overall Eye Health
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the launch of OTC Avenova Eye Health Support oral supplement featuring a combination of MaquiBright®,...

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor's Eczema Treatment on Two QVC® Shows on February 7
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Product Officer Audrey Kunin, MD will be a live on-air guest on two QVC network shows on...

NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Confere...

PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care Market
NASHVILLE, Tenn. & EMERYVILLE, Calif.--(BUSINESS WIRE)--PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships...

NovaBay Pharmaceuticals Announces the Launch of DERMAdoctor's TikTok Store in China and Expands Online Marketing in the U.S. and China
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the expansion of its lifestyle promotional video campaigns on TikTok and its Chinese counterpart Do...

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to the QVC® Network With DERMAdoctor's Eczema Balm
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces t...

NovaBay Pharmaceuticals Reports Third Quarter 2022 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2022 and provides a business upda...

NovaBay Pharmaceuticals Announces 1-for-35 Reverse Stock Split
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (the “Company”) (NYSE American: NBY) announces that today, following approval from the Company's stockholders obtained at the Comp...

NovaBay Pharmaceuticals to Hold Third Quarter 2022 Conference Call on November 14
EMERYVILLE, Calif.

NovaBay Pharmaceuticals Announces Expansion of DERMAdoctor Picture Porefect Collection with Launch of 15% Niacinamide Pore Minimizing Serum
EMERYVILLE, Calif.

NovaBay Pharmaceuticals to Present at the LD Micro Main Event XV
EMERYVILLE, Calif.

NovaBay Pharmaceuticals Announces Significant Orders for DERMAdoctor's Top-Selling Kakadu C Anti-Aging Serum ahead of the Holiday Season
EMERYVILLE, Calif.

NovaBay Pharmaceuticals' Avenova® and DERMAdoctor® Products to be Featured During the October 11-12 Amazon Prime Early Access Sale
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals' Avenova and DERMAdoctor products featured during Amazon Early Access Prime event.

NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Low Share Price
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on October 3, 2022 it received a notice from the NYSE American LLC that the Company's common sto...

NovaBay Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and sk...

NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: To My Fello...

NovaBay Pharmaceuticals to Present at the Virtual Life Sciences Investor Forum
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and sk...

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Showcase DERMAdoctor's Eczema Balm on Return QVC® Appearance
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products...

NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million

NovaBay Pharmaceuticals Reports Second Quarter 2022 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2022 and provides a business update. Fina...

NovaBay Pharmaceuticals to Hold Second Quarter 2022 Conference Call on August 11
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2022 after market c...

NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova® Lid and Lash Spray for Lash Extensions
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals targets the lash extension market with antimicrobial Avenova lid and lash spray.

NovaBay Pharmaceuticals' DERMAdoctor Products Now Available at Target.com and Urbanoutfitters.com
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and sk...